Q-omics provides the consensus-scored ZDHHC8 profile across patient tissues and cancer cell-line models. ZDHHC8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZDHHC8 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ZDHHC8 RNA expression shows 19,712 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ZDHHC8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC8 survival associations across molecular data types. ZDHHC8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC8 RNA expression–survival associations across cancer types. High ZDHHC8 expression shows unfavorable associations in ACC, KIRC and CESC, but favorable associations in READ, THYM and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZDHHC8 RNA expression.
This table summarizes ZDHHC8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZDHHC8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC8 shows higher tumor expression in HNSC, COAD, KIRC, KIRP, STAD and BLCA. The HNSC box plot shows higher ZDHHC8 RNA expression in tumor versus normal tissue (log2 FC = +1.266, t-test p < 0.001).
This table shows molecular features associated with ZDHHC8 in patient tissues and cancer cell lines. In patient samples, ZDHHC8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
